{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:42:42Z","timestamp":1790404962195,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002632","name":"Hallym University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002632","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002701","name":"Ministry of Education","doi-asserted-by":"publisher","award":["NRF-2020R1I1A3074575"],"award-info":[{"award-number":["NRF-2020R1I1A3074575"]}],"id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.coph.2021.06.008","type":"journal-article","created":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T13:07:56Z","timestamp":1627391276000},"page":"46-53","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Recent developments and strategies of Ebola virus vaccines"],"prefix":"10.1016","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3973-6755","authenticated-orcid":false,"given":"Ashish Ranjan","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeon-Hee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudarshini","family":"Nath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Soo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2021.06.008_bib1","first-page":"39","article-title":"Ebola haemorrhagic fever virus: pathogenesis, immune responses, potential prevention","volume":"54","author":"Marcinkiewicz","year":"2014","journal-title":"Folia Med Cracov"},{"key":"10.1016\/j.coph.2021.06.008_bib2","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.trstmh.2011.04.011","article-title":"A\u00a0limited outbreak of Ebola haemorrhagic fever in Etoumbi, Republic of Congo, 2005","volume":"105","author":"Nkoghe","year":"2011","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.coph.2021.06.008_bib3","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1177\/2051013615611017","article-title":"Clinical development of Ebola vaccines","volume":"3","author":"Sridhar","year":"2015","journal-title":"Ther Adv Vaccines"},{"key":"10.1016\/j.coph.2021.06.008_bib4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12967-014-0362-3","article-title":"Ebola: translational science considerations","volume":"13","author":"Chiappelli","year":"2015","journal-title":"J\u00a0Transl Med"},{"key":"10.1016\/j.coph.2021.06.008_bib5","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/rmv.1841","article-title":"Ebola virus outbreak, updates on current therapeutic strategies","volume":"25","author":"Elshabrawy","year":"2015","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.coph.2021.06.008_bib6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.7774\/cevr.2015.4.1.17","article-title":"Ebola outbreak in Western Africa 2014: what is going on with Ebola virus?","volume":"4","author":"Na","year":"2015","journal-title":"Clin Exp Vaccine Res"},{"key":"10.1016\/j.coph.2021.06.008_bib7","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.micinf.2014.11.007","article-title":"Ebola virus disease: a highly fatal infectious disease reemerging in West Africa","volume":"17","author":"To","year":"2015","journal-title":"Microb Infect"},{"key":"10.1016\/j.coph.2021.06.008_bib8","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1056\/NEJMoa1404505","article-title":"Emergence of Zaire ebola virus disease in Guinea","volume":"371","author":"Baize","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coph.2021.06.008_bib9","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.micinf.2014.11.012","article-title":"Development of therapeutics for treatment of Ebola virus infection","volume":"17","author":"Li","year":"2015","journal-title":"Microb Infect"},{"key":"10.1016\/j.coph.2021.06.008_bib10","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/phar.1545","article-title":"Treatment of ebola virus disease","volume":"35","author":"Kilgore","year":"2015","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.coph.2021.06.008_bib11","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.phrp.2014.09.006","article-title":"Ebola hemorrhagic fever and the current state of vaccine development","volume":"5","author":"Hong","year":"2014","journal-title":"Osong Publ Health Res Perspect"},{"key":"10.1016\/j.coph.2021.06.008_bib12","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1517\/14712598.2012.685152","article-title":"Current ebola vaccines","volume":"12","author":"Hoenen","year":"2012","journal-title":"Expet Opin Biol Ther"},{"key":"10.1016\/j.coph.2021.06.008_bib13","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.jaci.2014.12.012","article-title":"Ebola in the United States","volume":"135","author":"Lindblad","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.coph.2021.06.008_bib14","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s00134-015-3671-y","article-title":"Laboratory diagnosis of Ebola virus disease","volume":"41","author":"Martin","year":"2015","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.coph.2021.06.008_bib15","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1517\/14728222.2014.863877","article-title":"Could the Ebola virus matrix protein VP40 be a drug target?","volume":"18","author":"Stahelin","year":"2014","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.coph.2021.06.008_bib16","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1073\/pnas.1502619112","article-title":"Human Ebola virus infection results in substantial immune activation","volume":"112","author":"McElroy","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.coph.2021.06.008_bib17","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1038\/cdd.2015.67","article-title":"Molecular mechanisms of Ebola virus pathogenesis: focus on cell death","volume":"22","author":"Falasca","year":"2015","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.coph.2021.06.008_bib18","first-page":"11","article-title":"Viral emerging diseases: challenges in developing vaccination strategies","author":"Trovato","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.coph.2021.06.008_bib19","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2174\/1570163813666160902131603","article-title":"Peptides for anti-ebolavirus vaccines","volume":"13","author":"Kanduc","year":"2016","journal-title":"Curr Drug Discov Technol"},{"key":"10.1016\/j.coph.2021.06.008_bib20","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1080\/14760584.2020.1738225","article-title":"The Ebola virus glycoprotein and its immune responses across multiple vaccine platforms","volume":"19","author":"O'Donnell","year":"2020","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.coph.2021.06.008_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines8020241","article-title":"A\u00a0multi-filovirus vaccine candidate: Co-expression of ebola, Sudan, and marburg antigens in a single vector","volume":"8","author":"Sebastian","year":"2020","journal-title":"Vaccines"},{"key":"10.1016\/j.coph.2021.06.008_bib22","doi-asserted-by":"crossref","first-page":"385","DOI":"10.4103\/1995-7645.267581","article-title":"Ebola virus disease: recent advances in diagnostics and therapeutics","volume":"12","author":"Jagga","year":"2019","journal-title":"Asian Pac. J Trop Med"},{"key":"10.1016\/j.coph.2021.06.008_sref23","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1080\/21645515.2019.1651140","article-title":"Vaccines against Ebola virus and Marburg virus: recent advances and promising candidates","volume":"15","author":"Suschak","year":"2019","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.coph.2021.06.008_sref24","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s40259-018-0329-7","article-title":"Current ebola virus vaccine progress","volume":"33","author":"Marzi","year":"2019","journal-title":"BioDrugs"},{"key":"10.1016\/j.coph.2021.06.008_sref25","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1080\/14760584.2019.1698952","article-title":"Ebola vaccine trials: progress in vaccine safety and immunogenicity","volume":"18","author":"Matz","year":"2019","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.coph.2021.06.008_sref26","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1056\/NEJMra1901594","article-title":"Ebola","volume":"382","author":"Feldmann","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coph.2021.06.008_sref27","doi-asserted-by":"crossref","first-page":"100920","DOI":"10.1016\/j.isci.2020.100920","article-title":"Human antibody repertoire following ebola virus infection and vaccination","volume":"23","author":"Fuentes","year":"2020","journal-title":"iScience"},{"key":"10.1016\/j.coph.2021.06.008_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7001a1","article-title":"Use of ebola vaccine: recommendations of the advisory committee on immunization practices, United States, 2020","volume":"70","author":"Choi","year":"2021","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.coph.2021.06.008_bib29","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00134-020-05949-z","article-title":"Treatment of Ebola-related critical illness","volume":"46","author":"Kiiza","year":"2020","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.coph.2021.06.008_bib30","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1038\/s41591-019-0602-4","article-title":"Polyclonal and convergent antibody response to Ebola\u00a0virus vaccine rVSV-ZEBOV","volume":"25","author":"Ehrhardt","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.coph.2021.06.008_bib31","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0140-6736(18)30560-9","article-title":"Questionable efficacy of the rVSV-ZEBOV Ebola vaccine","volume":"391","author":"Metzger","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2021.06.008_bib32","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S1473-3099(20)30065-7","article-title":"Chimpanzee adenovirus type 3 vectored Ebola vaccine: expanding the field","volume":"20","author":"Bavari","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.coph.2021.06.008_sref33","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.coi.2021.03.008","article-title":"Ebola virus disease: current vaccine solutions","volume":"71","author":"Tomori","year":"2021","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.coph.2021.06.008_bib34","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1080\/21645515.2016.1238535","article-title":"Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: an open phase I\/II trial in healthy adults in Russia","volume":"13","author":"Dolzhikova","year":"2017","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.coph.2021.06.008_bib35","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1358\/dot.2021.57.1.3233361","article-title":"Recombinant vesicular stomatitis virus expressing Ebola virus glycoprotein (rVSV-EBOV), a new Ebola vaccine","volume":"57","author":"Kasereka","year":"2021","journal-title":"Drugs Today"},{"key":"10.1016\/j.coph.2021.06.008_bib36","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S1473-3099(20)30476-X","article-title":"Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial","volume":"21","author":"Pollard","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.coph.2021.06.008_bib37","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1001\/jama.2016.4218","article-title":"Safety and immunogenicity of novel adenovirus type 26- and modified vaccinia ankara-vectored ebola vaccines: a randomized clinical trial","volume":"315","author":"Milligan","year":"2016","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.coph.2021.06.008_bib38","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1172\/JCI81532","article-title":"Aerosolized Ebola vaccine protects primates and elicits lung-resident T cell responses","volume":"125","author":"Meyer","year":"2015","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.coph.2021.06.008_bib39","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S1473-3099(19)30614-0","article-title":"Safety and immunogenicity of a highly attenuated rVSVN4CT1-EBOVGP1 Ebola virus vaccine: a randomised, double-blind, placebo-controlled, phase 1 clinical trial","volume":"20","author":"Clarke","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.coph.2021.06.008_bib41","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.immuni.2021.01.015","article-title":"Immunotherapeutic strategies to target vulnerabilities in the Ebolavirus glycoprotein","volume":"54","author":"Misasi","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.coph.2021.06.008_bib43","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1089\/humc.2018.129","article-title":"Establishing China's national standard for the recombinant adenovirus type 5 vector-based ebola vaccine (Ad5-EBOV) virus titer","volume":"29","author":"Li","year":"2018","journal-title":"Hum Gene Ther Clin Dev"},{"key":"10.1016\/j.coph.2021.06.008_bib44","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0140-6736(16)32617-4","article-title":"Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"389","author":"Zhu","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2021.06.008_bib45","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/jat.3941","article-title":"Nonclinical safety assessment of repeated administration and biodistribution of Chad3-EBO-Z Ebola candidate vaccine","volume":"40","author":"Planty","year":"2020","journal-title":"J\u00a0Appl Toxicol"},{"key":"10.1016\/j.coph.2021.06.008_bib46","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1473-3099(15)00362-X","volume":"16","author":"Tapia","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.coph.2021.06.008_bib47","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S1473-3099(20)30019-0","article-title":"Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in children in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial","volume":"20","author":"Tapia","year":"2020","journal-title":"Lancet Infect Dis"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489221000813?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489221000813?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:59:39Z","timestamp":1761461979000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489221000813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":45,"alternative-id":["S1471489221000813"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2021.06.008","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent developments and strategies of Ebola virus vaccines","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2021.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}